LA MIRADA, CA, Apr 08, 2010– BioLargo, Inc. (OTC BB: BLGO) today announced that Bradley Caldwell, Inc. (BCI) (www.BradleyCaldwell.com) will begin distributing its award-winning Odor-No-More(TM) Animal Bedding Additive. Bradley Caldwell customers range from small “Mom and Pop,” Pet and Feed Stores and Tack Shops, to larger Lawn & Garden and “Superstore” retailers. BCI has over 5,000 dealers in 24 states from Maine to Michigan to North Carolina. Family owned and operated with a proven track record of experience and commitment to 100% customer satisfaction, Bradley Caldwell prides itself on delivering quality product selections like Odor-No-More.
“BCI is an important distribution partner for our Odor-No-More products. BCI provides a large area of coverage in a key region of the country,” stated Joe Provenzano, Odor-No-More, Inc. President. “This is a huge step in building product availability for the consuming public.”
About BioLargo, Inc.
BioLargo’s business strategy is to harness and deliver Nature’s Best Solution(TM) — free-iodine — in a safe, efficient, environmentally sensitive and cost-effective manner. BioLargo’s proprietary technology works by combining micro-nutrient salts with liquid from any source to deliver free-iodine on demand, in controlled dosages, in order to balance efficacy of performance with concerns about toxicity. BioLargo’s technology has potential commercial applications within global industries, including but not limited to agriculture, animal health, beach and soil environmental uses, consumer products, food processing, medical, and water. BioLargo’s strategic partner Ioteq IP Pty Ltd. was named a “Top 50 Water Company for the 21st Century” by The Artemis Project(TM); BioLargo markets Ioteq’s iodine-based water disinfection technology, the Isan system. The company’s website is www.BioLargo.com. The Odor-No-More products are sold by BioLargo’s wholly owned subsidiary, Odor-No-More, Inc. (www.OdorNoMore.com).
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, BioLargo’s filings and future filings with the Securities and Exchange Commission, including those set forth in the BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2008.
